Novartis will sell Bausch + Lomb its "front of eye" ophthalmology assets for up to $20.5 billion.

Published Date: 07 Jul 2023

For a brief time after the close, Novartis will continue to provide Xiidra to patients on behalf of Bausch + Lomb through transitional agreements.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

In Acute Myeloid Leukemia Diagnosed Recently, FLT3 Inhibitor Is Very Effective.

2.

Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.

3.

Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer

4.

A prostate cancer risk prediction algorithm could help target men at highest risk

5.

A smartphone app enhances the tracking of recovery following breast and gynecologic oncology surgery, according to JAMA.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot